CARMAT News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.02.18	CARMAT Advances the Internationalization of the PIVOTAL Study and Obtains the Approval to Perform Implants in Denmark (Businesswire)
31.01.18	CARMAT: 2018 Financial Calendar (Businesswire)
12.12.17	CARMAT announces the success of its capital increase for an amount of €52.9 million after full exercise of the increase option (Businesswire)
27.11.17	CARMAT: First Implantation in the Czech Republic within the Framework of the PIVOTAL Study International Expansion (Businesswire)
13.11.17	CARMAT Signs a Partnership Agreement with AddUp, the Michelin and Fives Joint Venture Specialized in 3D Printing (Businesswire)
30.10.17	CARMAT Accelerates the Internationalization of the PIVOTAL Study and Obtains the Approval to Perform Implants in the Czech Republic (Businesswire)
23.10.17	International Implant of the CARMAT Heart (Businesswire)
05.10.17	CARMAT Expands Its PIVOTAL Study Internationally, in Line with Its Clinical Strategy And CE Marking Process (Businesswire)
26.09.17	CARMAT: 2017 Half-Year Results (Businesswire)
01.09.17	CARMAT appoints Francesco Arecchi, previously Product Manager EMEA Structural Heart at Abbott, as Marketing Manager (Businesswire)
06.07.17	CARMAT Appoints Wenzel Hurtak, Previously Business Director New Products at Contract Medical International GmbH, as Director of Manufacturing (Businesswire)
25.01.17	Two Cardiology Experts Join CARMAT’s Board of Directors as Independent Members (Businesswire)
08.09.16	CARMAT: 2016 half-year results in line with the progress achieved by the Company (Businesswire)
01.09.16	Stéphane Piat, Previously Division Vice President of Abbott in California, Has Been Appointed CEO of CARMAT (Businesswire)
01.09.16	CARMAT announces the departure of Marcello Conviti, CEO (Businesswire)
29.08.16	CARMAT Announces the Start of the PIVOTAL Study (Businesswire)
13.07.16	CARMAT Has Obtained the Necessary Approvals to Begin the PIVOTAL Study in France (Businesswire)
07.07.16	CARMAT: Extraordinary General Meeting of August 10, 2016 (Businesswire)
23.06.16	CARMAT Has Begun, with DEKRA, the CE Certification Process for Its Bioprosthetic Artificial Heart (Businesswire)
28.04.16	CARMAT: Professor Carpentier finalist for the European Inventor Award 2016 (Businesswire)
27.04.16	CARMAT Completes Its €50.0m Reserved Capital Increase (Businesswire)
25.04.16	CARMAT to Participate in the 36th ISHLT Annual Meeting in Washington DC (Businesswire)
12.04.16	CARMAT: The Combined Shareholders’ Meeting of April 12, 2016 Approves the Resolutions Pertaining to the Reserved Capital Increase and the Group’s Governance (Businesswire)
26.02.16	50.0 Million Euro Equity Financing to Reinforce CARMAT’s Cash Resources (Businesswire)
26.02.16	2015 Annual Results in Line With CARMAT’s Stage of Development (Businesswire)
21.01.16	Information regarding the Feasibility study of the CARMAT bioprosthetic artificial heart (Businesswire)
22.12.15	Update on the Feasibility Study of The CARMAT Bioprosthetic Artificial Heart (Businesswire)
24.11.15	CARMAT Obtains Regulatory Approval to Finalize Its Clinical Feasibility Study (Businesswire)
10.09.15	CARMAT: 2015 Half-Year Results in Line with the Company’s Stage of Development (Businesswire)
03.09.15	The 3rd Patient Implanted with a CARMAT Heart at the Georges Pompidou European Hospital on April 8, 2015 Has Returned Home (Businesswire)
31.08.15	Interim Results of the Feasibility Study Presented at the ESC Congress in London (Businesswire)
31.08.15	CARMAT: Interim Results of the Feasibility Study Presented at the ESC Congress in London (Businesswire)
26.05.15	CARMAT Appoints Benoît de la Motte as CFO (Businesswire)
05.05.15	Initial Details of the Analysis of the CARMAT Heart Implanted in the Second Patient (Businesswire)
04.05.15	CARMAT: Update on the Feasibility Study of the First Bioprosthetic Artificial Heart (Businesswire)
28.04.15	Implantation of the CARMAT Heart in a 3rd Patient at the Georges Pompidou European Hospital (Businesswire)
30.03.15	Airbus Group Joins the CARMAT Board of Directors (Businesswire)
11.02.15	CARMAT: 2014 Annual Results (Businesswire)
26.01.15	CARMAT Subscribes to a New Contingent Equity Line with Kepler Cheuvreux (Businesswire)
22.01.15	CARMAT Will Benefit from the European SEED1 Program That Supports Innovative Therapy Developers Seeking Reimbursement (Businesswire)
19.01.15	The patient who received a CARMAT bioprosthetic heart in Nantes on August 5, 2014 has been discharged home (Businesswire)
12.01.15	CARMAT: 2015 Financial Agenda (Businesswire)
16.12.14	CARMAT secures its cash position by reaching milestone n°5 of its contract with Bpifrance, and receives €5.3 million (Businesswire)
03.12.14	CARMAT Wins the 2014 INPI* Award in the "Patent” Category (Businesswire)
21.10.14	CARMAT: 2014 Half-Year Results (Businesswire)
09.10.14	CARMAT is Participating in the 28th EACTS Annual Meeting in Milan (Italy) (Businesswire)
30.09.14	CARMAT Publishes Its 6th Shareholder Newsletter (Businesswire)
23.09.14	CARMAT Receives the Microns D’or Honorary Award (Businesswire)
22.09.14	CARMAT Appoints Eric Richez to Director of Business Development (Businesswire)
19.09.14	CARMAT: Press Release (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CARMAT

Aktien Top/Flop

Meistgelesene Nachrichten